Recently there have been reports that N-NItrosodimethylamine (NDMA) was found in the generic drug metformin.  The FDA has been investigating the reports and has posted the laboratory results showing N- Nitrosodimethylamine (NDMA) levels in some metformin products. The results determined that the levels of NDMA in metformin products tested ranged from not detectable to low levels. To date, no sample of metformin that the FDA has tested exceeds the acceptable daily intake for NDMA. FDA has not recommended metformin recalls in the U.S.  FDA will continue to monitor NDMA in metformin, along with other drugs products, and will provide timely updates of new developments, including product recalls. For more information about NDMA, visit FDA’s nitrosamines webpage.